it sounds like many of the loudest whingers bought in at high prices because they believed purchasing generics was a good move. and your stuck with over a $1 buy in. it was obviously a bad purchase. its taken years to correct.
the generics are now a much smaller part of the business - a huge turnover is irrelevant. losses are due to non cash writeoffs of the value of the generics. the reduction in turnover due to drastic reductions in generic sales is not a bad thing.
all other sectors of the business are pretty profitable.
metrics and manufacturing is exploding.
the business model of creating a sales force to market to dermatologists is fantastic. instead of just selling there own 3 o4 they now have 25. The other manufacturers cant afford a dedicated sales force so they are using the MYX sales force to market their drugs. Some of these drugs are big sellers. 2 of the latest - especially. MYX seems to have proven the model, worked hard to get some on board, and now have a compelling business model in place. these things take time.
i had a conversation with head office today about the sales arrangements and was told the finer points of how it works. MYX would do themselves a big favour if they put out some material or a meeting to explain the system they have implemented. its brilliant and with 25 drugs involved is going to increase turnover with higher percentage profits.
can any whingers explain the MYX model for selling the products.!!! HOW MUCH DO YOU REALLY KNOW ABOUT MYX.
- Forums
- ASX - By Stock
- MYX
- Ann: 2022 Half Year Investor Presentation
MYX
mayne pharma group limited
Add to My Watchlist
0.20%
!
$5.08

Ann: 2022 Half Year Investor Presentation, page-119
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M |
Open | High | Low | Value | Volume |
$5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 810 | $5.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.15 | 2033 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 810 | 5.080 |
2 | 3150 | 5.040 |
1 | 600 | 5.030 |
3 | 3000 | 5.000 |
1 | 10000 | 4.980 |
Price($) | Vol. | No. |
---|---|---|
5.150 | 2033 | 2 |
5.180 | 2396 | 2 |
5.190 | 5000 | 1 |
5.200 | 157 | 1 |
5.210 | 5000 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online